Chemed (NYSE:CHE) Issues FY 2026 Earnings Guidance

Chemed (NYSE:CHE) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 25.000-25.750 for the period, compared to the consensus earnings per share estimate of 24.010. The company issued revenue guidance of -.

Chemed Stock Down 0.8%

Shares of NYSE:CHE traded down $4.51 during trading on Thursday, hitting $534.85. 38,328 shares of the company were exchanged, compared to its average volume of 222,086. The stock has a market cap of $7.10 billion, a price-to-earnings ratio of 26.84, a P/E/G ratio of 1.91 and a beta of 0.52. Chemed has a fifty-two week low of $365.20 and a fifty-two week high of $551.68. The firm has a fifty day moving average price of $463.37 and a two-hundred day moving average price of $435.25. The company has a current ratio of 0.85, a quick ratio of 0.83 and a debt-to-equity ratio of 0.11.

Chemed (NYSE:CHE) last announced its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.60 by $0.46. The company had revenue of $673.25 million for the quarter, compared to analysts’ expectations of $665.04 million. Chemed had a return on equity of 30.64% and a net margin of 10.60%.The business’s revenue was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.27 EPS. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. As a group, research analysts anticipate that Chemed will post 22.67 earnings per share for the current fiscal year.

Chemed Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th were paid a $0.60 dividend. The ex-dividend date was Thursday, May 28th. This represents a $2.40 dividend on an annualized basis and a yield of 0.4%. Chemed’s dividend payout ratio (DPR) is currently 13.08%.

Analysts Set New Price Targets

Several research firms have recently weighed in on CHE. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Wall Street Zen cut Chemed from a “buy” rating to a “hold” rating in a report on Monday, June 8th. Bank of America reiterated a “neutral” rating on shares of Chemed in a report on Wednesday. Weiss Ratings raised Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, July 17th. Finally, Royal Bank Of Canada restated a “sector perform” rating on shares of Chemed in a research note on Thursday. One research analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Chemed has an average rating of “Hold” and a consensus price target of $480.25.

Insider Buying and Selling at Chemed

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $421.13, for a total value of $842,260.00. Following the completion of the sale, the chief executive officer owned 90,219 shares of the company’s stock, valued at approximately $37,993,927.47. The trade was a 2.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Andrea R. Lindell sold 1,347 shares of the business’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $447.33, for a total transaction of $602,553.51. Following the completion of the sale, the director directly owned 4,578 shares of the company’s stock, valued at approximately $2,047,876.74. The trade was a 22.73% decrease in their position. The SEC filing for this sale provides additional information. 3.33% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Geneos Wealth Management Inc. boosted its position in shares of Chemed by 330.4% during the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock worth $61,000 after acquiring an additional 76 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Chemed by 67.0% in the second quarter. Arrowstreet Capital Limited Partnership now owns 11,365 shares of the company’s stock valued at $5,534,000 after buying an additional 4,560 shares in the last quarter. Marshall Wace LLP bought a new position in Chemed in the second quarter valued at about $579,000. Brown Advisory Inc. grew its position in Chemed by 36.9% in the second quarter. Brown Advisory Inc. now owns 549 shares of the company’s stock valued at $267,000 after acquiring an additional 148 shares during the last quarter. Finally, Cerity Partners LLC grew its position in Chemed by 237.7% in the second quarter. Cerity Partners LLC now owns 4,451 shares of the company’s stock valued at $2,165,000 after acquiring an additional 3,133 shares during the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.